BR112022023949A2 - Composições e métodos para tratar dor não inflamatória em indivíduos com artrite reumatoide - Google Patents

Composições e métodos para tratar dor não inflamatória em indivíduos com artrite reumatoide

Info

Publication number
BR112022023949A2
BR112022023949A2 BR112022023949A BR112022023949A BR112022023949A2 BR 112022023949 A2 BR112022023949 A2 BR 112022023949A2 BR 112022023949 A BR112022023949 A BR 112022023949A BR 112022023949 A BR112022023949 A BR 112022023949A BR 112022023949 A2 BR112022023949 A2 BR 112022023949A2
Authority
BR
Brazil
Prior art keywords
individuals
rheumatoid arthritis
inflammatory pain
compositions
methods
Prior art date
Application number
BR112022023949A
Other languages
English (en)
Portuguese (pt)
Inventor
Ford Kerri
VAN HOOGSTRATEN Hubert
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of BR112022023949A2 publication Critical patent/BR112022023949A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022023949A 2020-05-29 2021-05-27 Composições e métodos para tratar dor não inflamatória em indivíduos com artrite reumatoide BR112022023949A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063032035P 2020-05-29 2020-05-29
US202063077378P 2020-09-11 2020-09-11
EP21315081 2021-05-11
PCT/IB2021/054652 WO2021240436A1 (en) 2020-05-29 2021-05-27 Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
BR112022023949A2 true BR112022023949A2 (pt) 2022-12-27

Family

ID=76269781

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023949A BR112022023949A2 (pt) 2020-05-29 2021-05-27 Composições e métodos para tratar dor não inflamatória em indivíduos com artrite reumatoide

Country Status (12)

Country Link
US (1) US20230192871A1 (https=)
EP (1) EP4157450A1 (https=)
JP (1) JP7841752B2 (https=)
KR (1) KR20230018443A (https=)
CN (1) CN115697486A (https=)
AU (1) AU2021279412A1 (https=)
BR (1) BR112022023949A2 (https=)
CA (1) CA3180041A1 (https=)
CO (1) CO2022017828A2 (https=)
IL (1) IL298087A (https=)
MX (1) MX2022015030A (https=)
WO (1) WO2021240436A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
AU2015317905A1 (en) * 2014-09-16 2017-03-16 Regeneron Pharmaceuticals, Inc. Compositions for improving the health related quality of life of rheumatoid arthritis patients

Also Published As

Publication number Publication date
WO2021240436A1 (en) 2021-12-02
JP7841752B2 (ja) 2026-04-07
CO2022017828A2 (es) 2022-12-20
IL298087A (en) 2023-01-01
KR20230018443A (ko) 2023-02-07
MX2022015030A (es) 2023-01-04
US20230192871A1 (en) 2023-06-22
JP2023527200A (ja) 2023-06-27
EP4157450A1 (en) 2023-04-05
AU2021279412A1 (en) 2023-02-02
CA3180041A1 (en) 2021-12-02
CN115697486A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
BR112014008764A2 (pt) composições para o tratamento de artrite reumatóide e métodos de seu uso
BR112022023949A2 (pt) Composições e métodos para tratar dor não inflamatória em indivíduos com artrite reumatoide
CR20180465A (es) Composiciones y métodos para tratar artritis reumatoide
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
PE20240638A1 (es) Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
CO2021015660A2 (es) Métodos de diagnóstico y tratamiento de la artritis reuma-toide
Hatfield et al. Chain stability in trading networks
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
BR112021024445A2 (pt) Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide
BR112021020612A2 (pt) Métodos para tratamento de sujeitos com artrite psoriática
Ali et al. Predictability of engineering students’ performance at the University of Engineering and Technology, Peshawar from admission test conducted by educational testing and evaluation agency (ETEA), NWFP, Pakistan
Sawai et al. Trust and commitment in maintaining marriage among teachers in commuting marriage in Kota Kinabalu Sabah
Turska-Kawa et al. Direct democracy in Poland. Between democratic centralism and civic localism
BR112022017129A2 (pt) Compostos para uso em condições autoimunes
Ganshina et al. Sustainable Development Strategy as a Paradigm for Social and Cultural Stability
Ning Roads: Robust Seismic Sources
Chunpuang et al. The Naming of Schools in Bangkok: Case Study Origin of Name
Shchipin On the history of one teachers’ family in a Cossack village. To the 150th anniversary of the Cossack village Neftyanaya
Брунер Êàäðîâàÿ ïîëèòèêà Ìèíèñòåðñòâà âíóòðåííèõ äåë êàê èíñòðóìåíò óïðàâëåíèÿ ñîòðóäíèêàìè ïîëèöèè1
EA202192416A1 (ru) Способы лечения субъектов с псориатическим артритом
Быкова Bykova Sofya A. Undergraduate of Law Faculty Vladimir Branch of RANEPA, Vladimir
Cohen Update on the Latest Programs and Events in Your Tort Trial & Insurance Practice Section
Валькова et al. ÒÓÐÈÇÌ Â ÌÀËÛÕ ÃÎÐÎÄÀÕ: ÇÀÐÀÉÑÊ
Foreman Seventh European Set Theory Conference